Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06099106

Safety and Performance of ENDOMATIC SEPIOLA Left Atrial Appendage (LAA) Closure Device

Led by Endomatic Ltd. · Updated on 2025-08-17

15

Participants Needed

5

Research Sites

208 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The study is designed to evaluate the safety and performance of the ENDOMATIC SEPIOLA Left Atrial Appendage (LAA) Closure Device in Patients with non-valvular Atrial Fibrillation, who are at increased risk for stroke, and that cannot take, or have a reason to seek an alternative, to long-term anticoagulation therapy. Potential patients who are candidates for LAA closure will be screened to confirm that all inclusion/exclusion criteria are met, with final eligibility confirmation on day of procedure. All enrolled subjects who went through the procedure will be followed during the procedure to hospital discharge. Additional follow up time points are scheduled at 45 days, 6 months and 12 months post procedure.

CONDITIONS

Official Title

Safety and Performance of ENDOMATIC SEPIOLA Left Atrial Appendage (LAA) Closure Device

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Calculated CHA2DS2-VASc score of 2 or greater
  • Non-eligible for or have a reason to seek a non-pharmacologic alternative to long-term oral anticoagulants
  • Documented non-valvular atrial fibrillation
  • Suitable for vascular or cardiac intervention procedure
  • Suitable left atrial appendage anatomical measurements for the study device
Not Eligible

You will not qualify if you...

  • Requires anticoagulation for conditions other than atrial fibrillation
  • New York Heart Association (NYHA) classification IV
  • Complex congenital heart disease
  • Presence of circumflex coronary artery stent
  • Has a prosthetic heart valve in any position
  • Has atrial septal defect closure or an ASD/PFO device
  • Presence of intracardiac thrombus
  • Any prior cardiac surgery
  • Left ventricular ejection fraction (LVEF) less than 35%
  • Moderate or severe mitral valve stenosis

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

Israeli-Georgian Medical Research Clinic Helsicore

Tbilisi, Georgia, 0112

Completed

2

Tbilisi Heart and Vascular Clinic

Tbilisi, Georgia, 0159

Completed

3

Vilnius university hospital Santaros Klinikos

Vilnius, Lithuania

Actively Recruiting

4

Uniwersytecki Szpital Kliniczny w Poznaniu

Poznan, Poland

Actively Recruiting

5

Ezgu Niyat

Tashkent, Uzbekistan

Actively Recruiting

Loading map...

Research Team

B

Boaz Schwarz

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here